When was Santa Ana Bio founded?

Santa Ana Bio was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Santa Ana Bio located?

Santa Ana Bio is headquartered in Alameda, United States.

How many employees does Santa Ana Bio have?

As of Feb 28, 2026, the latest employee count at Santa Ana Bio is 36.

Is Santa Ana Bio a funded company?

Santa Ana Bio is a funded company, having raised a total of $168M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 28, 2023.

When was the latest funding round of Santa Ana Bio?

Santa Ana Bio's latest funding was a $***** Series B round on May 16, 2024, with participation from 4 investors.

Where does Santa Ana Bio rank among its competitors?

Santa Ana Bio ranks 72nd amongst 487 active competitors, of which 187 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was STAR Therapeutics, which secured $125M in Sep, 2025.

Who are the top competitors of Santa Ana Bio?

Santa Ana Bio's top competitors include BioNTech, ADMA Biologics and Dren Bio. Among them, STAR Therapeutics secured the most recent funding round in September, 2025.

Santa Ana Bio - 2026 Company Profile, Team, Funding & Competitors

Santa Ana Bio is a series B company based in Alameda (United States), founded in 2021 by Danny Wells and Aliza Apple. It operates as a Developer of precision medicines for autoimmune diseases.. Santa Ana Bio has raised $168M in funding from Google Ventures and Versant Ventures. The company has 487 active competitors, including 187 funded and 130 that have exited. Its top competitors include companies like BioNTech, ADMA Biologics and Dren Bio.

Company Details

Developer of precision medicines for autoimmune diseases. The company offers programs across multiple indications, leveraging single-cell genomics and advanced analytics which allow patients with specialized deep-cell profiling.

Website: santaanabio.com
Email ID: *****@santaanabio.com

Key Metrics

Founded Year

2021

Location

Alameda, United States

Stage

Series B

Total Funding

$168M in 2 rounds

Latest Funding Round

Series B, May 16, 2024, $*****

Investors

Google Ventures & 5 more

Ranked

72^nd among 487 active competitors

Employee Count

36 as on Feb 28, 2026

Similar Companies

BioNTech & 573 more

View Santa Ana Bio's full profile

Santa Ana Bio has raised a total funding of $168M over 2 rounds. Its first funding round was on Feb 28, 2023. Its latest funding round was a Series B round on May 16, 2024 for $*****. 4 investors participated in its latest round. Santa Ana Bio has 6 institutional investors.

Here is the list of recent funding rounds of Santa Ana Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 16, 2024	1375208	Series B	5942493	5483262	8614849	1324365
Feb 28, 2023	1825733	Series A	3299126	5694677	Versant Ventures	Google Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Santa Ana Bio's funding rounds and investors

The founders of Santa Ana Bio are Danny Wells and Aliza Apple. Peter Emtage is the CEO of Santa Ana Bio.

Here are the details of Santa Ana Bio's key team members:

Danny Wells: Co-Founder of Santa Ana Bio.
Aliza Apple: Co-Founder and SVP of Portfolio, Partnerships, Strategy of Santa Ana Bio.
Peter Emtage: CEO of Santa Ana Bio.
Contact Info: 1 email address

View details of Santa Ana Bio's Founder profiles and Board Members

Santa Ana Bio's employee count trend

Santa Ana Bio has 36 employees as of Feb 26. Here is Santa Ana Bio's employee count trend over the years:

Uncover Santa Ana Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Santa Ana Bio include BioNTech, ADMA Biologics and Dren Bio. Here is the list of Top 10 competitors of Santa Ana Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Redmile Group, Fidelity Investments & 28 others	72/100
2nd	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	71/100
3rd	Dren Bio 2019, San Carlos (United States), Series B	Developer of therapeutic antibodies for the treatment of cancer, autoimmune, and other serious diseases	$156M	Aisling Capital, HBM Healthcare Investments ... & 13 others	69/100
4th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
5th	Apellis Pharmaceuticals 2008, Crestwood (United States), Public	Developer of therapeutics for the treatment of rare diseases	$213M	Sectoral, Hillhouse & 21 others	68/100
6th	PureTech Health 2001, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual	67/100
7th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Deerfield & 5 others	67/100
8th	Adagene 2012, Suzhou (China), Public	Developer of immunotherapy for the treatment of cancer	$155M	F-Prime Capital, WuXi AppTec & 12 others	67/100
9th	Vera Therapeutics 2016, San Francisco (United States), Public	Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases	$197M	Abingworth, Citadel & 13 others	66/100
10th	STAR Therapeutics 2018, San Francisco (United States), Series D	Developer of antibody therapies for multiple diseases	$215M	Viking Global Investors, Sanofi Ventures ... & 17 others	66/100
72nd	Santa Ana Bio 2021, Alameda (United States), Series B	Developer of precision medicines for autoimmune diseases.	$168M	Access Industries, RTW Investments & 4 others	60/100